Index
RUT
Market Cap
2.03B
Enterprise Value
2.29B
Income
-77.39M
Sales
208.78M
Book/sh
1.37
Cash/sh
0.27
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
435
IPO
Nov 20, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
9.71
P/B
5.68
P/C
28.73
P/FCF
-
EV/EBITDA
79.93
EV/Sales
10.95
Quick Ratio
2.98
Current Ratio
4.05
Debt/Eq
0.86
LT Debt/Eq
0.86
Option/Short
Yes / Yes
EPS (ttm)
-0.53
EPS next Y
-0.10
EPS next Q
-0.06
EPS this Y
62.67%
EPS next Y
7.16%
EPS next 5Y
37.17%
EPS past 3/5Y
- -
Sales past 3/5Y
-40.53% -8.15%
EPS Y/Y TTM
61.09%
Sales Y/Y TTM
-3.28%
EPS Q/Q
69.44%
Sales Q/Q
8.53%
Insider Own
25.31%
Insider Trans
-0.08%
Inst Own
82.05%
Inst Trans
7.32%
ROA
-10.31%
ROE
-32.90%
ROIC
-20.35%
Gross Margin
34.32%
Oper. Margin
-13.40%
Profit Margin
-37.07%
SMA20
5.19%
SMA50
4.40%
SMA200
48.59%
Trades
Shs Outstand
148.89M
Shs Float
111.28M
52W High
9.42 -17.09%
52W Low
2.55 206.88%
Volatility
6.73% 7.21%
ATR (14)
0.48
RSI (14)
53.56
Beta
0.62
Rel Volume
0.02
Avg Volume
3.15M
Volume
2,735
Perf Week
3.03%
Perf Month
-1.14%
Perf Quarter
21.46%
Perf Half Y
106.07%
Perf YTD
140.31%
Perf Year
148.73%
Perf 3Y
16.22%
Perf 5Y
-82.73%
Perf 10Y
-
Prev Close
7.81
Price
7.81
Change %
0.00%
Analysts 15 incl. previous ratings
Rating Distribution 6 Buy · 8 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Oct 05, 2026 Initiated T TD Cowen
Buy $9 +15.2% Feb 26, 2025 Downgrade R
Outperform → Neutral $9 → $3 -61.6% Dec 19, 2024 Initiated G
Neutral Dec 05, 2024 Downgrade G Goldman
Neutral → Sell $4.25 -45.6% Nov 14, 2024 Initiated W
Peer Perform Nov 08, 2024 Downgrade W
Outperform → Mkt Perform Aug 28, 2024 Initiated W Wells Fargo
Overweight $10 +28.0% Aug 13, 2024 Downgrade M Morgan Stanley
Overweight → Equal-Weight $11 → $10 +28.0% Apr 10, 2024 Initiated C
Buy $15 +92.1% Dec 12, 2023 Upgrade B BofA Securities
Neutral → Buy $10 → $8 +2.4% Aug 08, 2023 Downgrade K KeyBanc Capital Markets
Overweight → Sector Weight May 23, 2023 Downgrade C
Outperform → Neutral $18 → $14 +79.3% May 09, 2023 Downgrade G Goldman
Buy → Neutral Jan 05, 2023 Downgrade U UBS
Buy → Neutral $20 → $16 +104.9% Dec 14, 2022 Initiated D Deutsche Bank
Buy $25 +220.1% Dec 07, 2022 Initiated R RBC Capital Mkts
Outperform $22 +181.7% Nov 03, 2022 Downgrade B BofA Securities
Buy → Neutral $32 → $17 +117.7% Aug 25, 2022 Initiated C
Outperform $34 +335.3% Aug 05, 2021 Resumed C
Outperform $44 +463.4% Dec 16, 2020 Initiated K KeyBanc Capital Markets
Overweight $33 +322.5%
Oct-29-26 04:01PM
Oct-27-26 06:31PM
(Earnings Whispers)
+8.97%
Oct-14-26 04:01PM
Sep-29-26 04:01PM
Aug-06-26 04:01PM
04:02PM
Loading…
Jul-22-26 04:02PM
Jul-20-26 04:02PM
Jun-16-26 08:30AM
Jun-03-26 08:30AM
May-18-26 04:00PM
May-07-26 04:01PM
Apr-20-26 04:05PM
Feb-26-26 02:11AM
Feb-25-26 07:25PM
04:01PM
05:05PM
Loading…
Feb-09-26 05:05PM
Nov-10-25 08:00AM
Nov-07-25 12:12AM
Nov-06-25 06:15PM
04:01PM
Nov-04-25 09:05AM
Oct-22-25 04:01PM
Aug-12-25 03:07AM
Aug-11-25 07:00PM
04:05PM
Jul-28-25 05:08PM
Jun-25-25 04:01PM
Jun-09-25 08:30AM
Jun-03-25 10:00AM
May-21-25 04:22PM
04:05PM
Loading…
04:05PM
May-20-25 08:00AM
May-14-25 04:00PM
May-13-25 09:30AM
(Thomson Reuters StreetEvents)
03:11AM
May-12-25 05:20PM
04:06PM
May-08-25 05:10PM
May-07-25 07:10PM
May-05-25 05:47AM
May-01-25 05:20PM
07:30AM
Apr-24-25 12:27PM
Apr-22-25 05:45AM
Apr-16-25 06:10PM
Apr-15-25 09:35AM
Apr-14-25 01:13PM
Apr-11-25 01:31PM
Apr-10-25 11:34AM
04:37AM
Apr-04-25 02:34PM
Apr-03-25 06:21PM
Apr-01-25 01:23PM
Mar-26-25 11:10AM
Mar-25-25 12:49PM
Mar-24-25 02:33PM
Mar-22-25 10:30AM
Mar-21-25 08:00PM
01:43PM
Mar-20-25 09:00PM
Mar-18-25 04:05PM
05:45AM
Mar-17-25 02:22AM
Mar-16-25 09:32AM
Mar-08-25 10:15AM
Feb-28-25 09:31AM
Feb-27-25 06:37PM
Feb-25-25 06:00AM
Feb-24-25 08:00AM
Feb-04-25 04:01PM
Feb-03-25 06:00AM
Jan-28-25 04:01PM
Jan-20-25 11:02PM
Jan-08-25 04:10PM
Dec-20-24 07:15AM
Dec-05-24 04:05PM
Nov-12-24 08:05AM
Nov-09-24 06:51AM
Nov-08-24 02:20PM
(Thomson Reuters StreetEvents)
-35.27%
03:15AM
02:34AM
Nov-07-24 04:01PM
04:01PM
Oct-15-24 04:05PM
Oct-09-24 08:03AM
Sep-24-24 08:12AM
Aug-28-24 07:49AM
Aug-12-24 08:05AM
Aug-08-24 12:45AM
Aug-07-24 04:05PM
Jul-29-24 04:05PM
Jul-10-24 08:00AM
Jul-02-24 04:00PM
Jun-20-24 09:15AM
Jun-17-24 09:54AM
Jun-12-24 02:38AM
May-17-24 11:52AM
May-13-24 08:00AM
May-09-24 04:18PM
(Insider Monkey)
+11.16%
+6.09%
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ORESHACK KURT General Counsel Jun 10 '26 Sale 5.10 25,000 127,500 335,767 Jun 10 05:06 PM ORESHACK KURT General Counsel Jun 09 '26 Sale 5.06 25,000 126,500 360,767 Jun 10 05:06 PM ORESHACK KURT Officer Jun 10 '26 Proposed Sale 5.10 25,000 127,500 Jun 10 12:00 PM ORESHACK KURT Officer Jun 09 '26 Proposed Sale 5.06 25,000 126,500 Jun 09 10:31 AM PRAHALAD MURALI Former Director Dec 23 '25 Proposed Sale 3.33 3,951 13,138 Dec 23 03:00 PM Hopfield Jessica Former Director Dec 19 '25 Proposed Sale 3.48 53,951 187,526 Dec 19 04:38 PM LUCIER GREGORY T Director Dec 05 '25 Buy 3.70 51,472 190,446 106,595 Dec 09 04:36 PM LUCIER GREGORY T Director Dec 08 '25 Buy 3.67 48,528 178,098 155,123 Dec 09 04:36 PM Brust Bernd Chief Executive Officer Nov 13 '25 Buy 3.25 216,212 702,689 466,771 Nov 17 04:48 PM Brust Bernd Chief Executive Officer Nov 11 '25 Buy 3.24 157,201 509,331 157,201 Nov 13 05:27 PM Brust Bernd Chief Executive Officer Nov 12 '25 Buy 3.21 93,358 299,679 250,559 Nov 13 05:27 PM
Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm's brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Chairman of the Board Mr. Robert Andrew Eckert M.B.A.
CEO & Director Mr. Bernd Brust
EVP & Chief Financial Officer Mr. Rajesh J. Asorpota
Executive VP Mr. Kurt A. Oreshack J.D.
Executive VP & GM of Cygnus Technologies Ms. Christine Dolan
